683 Capital Management’s Pyxis Oncology PYXS Stock Holding History

683 Capital Management’s Portfolio PYXS Stock Details PYXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.31M	Buy	896,263 +4,353	+0.5%	+$6.56K	0.07%	129
2025 Q4	$1.03M	Buy	891,910 +366,910	+70%	+$1.29M	0.04%	139
2025 Q3	$1.17M	Sell	525,000 -20,000	-4%	-$28.8K	0.06%	119
2025 Q2	$600K	Sell	545,000 -5,000	-0.9%	-$5.63K	0.04%	117
2025 Q1	$539K	Buy	550,000 +135,000	+33%	+$180K	0.04%	127
2024 Q4	$647K	Buy	415,000 +344	+0.1%	+$992	0.04%	136
2024 Q3	$1.52M	Buy	+414,656	New	+$1.45M	0.12%	95

Other funds holding PYXS

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

GGI

GordonMD Global Investments Beverely Hills, California $144M AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

683 Capital Management's PYXS Position: Q1 2026 in Review

683 Capital Management increased its Pyxis Oncology (PYXS) stake by 0.49% in Q1 2026, buying an estimated $6.56K and bringing the position to 896,263 shares worth $1.31M. The position accounts for 0.07% of the portfolio, ranked #129.

683 Capital Management first reported a position in PYXS in Q3 2024 and has held it in 7 quarters since. The position peaked at $1.52M in Q3 2024. 78 funds tracked by Wall St. Rank hold PYXS as of Q1 2026.

683 Capital Management held 896,263 shares of Pyxis Oncology worth $1.31M as of Q1 2026.
683 Capital Management bought 4,353 Pyxis Oncology shares in Q1 2026, an estimated $6.56K.
Pyxis Oncology made up 0.07% of 683 Capital Management's portfolio in Q1 2026, its #129 holding.
683 Capital Management first reported a position in Pyxis Oncology in Q3 2024 and has held it in 7 quarters since.
683 Capital Management's Pyxis Oncology position peaked at $1.52M in Q3 2024.
78 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.